Login
Navigate Fool.com
Will PRX beat
the market?
Community Rating: 3 Stars: Appealing

0.00 0.00 (0.00%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open 0.00
Previous Close 0.00
Daily Range 0.00 - 0.00
52-Week Range 0.00 - 0.00
Market Cap 0.0000
P/E Ratio 0.00
Dividend (Yield) 0.00 (0.0%)
Volume 0
Average Daily Volume 0
Current FY EPS 4.05

How do you think PRX
will perform against the market?

Top PRX Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

A Generic Double Whammy

Teva's sales are hurt by generic competition and lost sales of its own generics.

Small-Cap Biotechs with Blockbuster Potential: Hugh Cleland

A Brief Bounce for This Biotech

Horizon Pharmaceuticals enjoys a short-lived bounce following Q3 results.

Why Does Billionaire Thomas Steyer’s Farallon Love This Pharmaceutical Company?

Wild-Eyed Optimism About Horizon's Plummet

Horizon Pharma's big one-day drop could mean good news.

ADT, Pentair to Gain Spots on S&P 500, Replacing Lexmark, DeVry

New Issue-Par Pharmaceutical sells $490 mln notes

TEXT-S&P assigns Par Pharmaceutical prelim 'B+' rating

BRIEF-Moody's: Par upsized term loan credit negative; no rtg impact

BRIEF - Moody's rates Par Pharmaceuticals

See More PRX News...

Sector

Healthcare

Industry

Drugs

Par Pharmaceutical Companies, Inc. (PRX) Description

The Company, through its subsidiary Par Pharmaceutical, Inc., is engaged in the development, manufacture and distribution of generic pharmaceuticals and branded pharmaceuticals in the United States. Website:

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks